ArticleLeukemia2022
Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP.
Article in Leukemia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02280993 (Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse Who Are Eligible for High Dose Treatment Followed by Autologous Peripheral Blood Stem Cell Transplantation (ASCT)
Who cites it
15 citing papers in PubMed, 18 citations in OpenAlex.
- Tumor-specific immune responses and biomarkers in pediatric patients with high-risk Hodgkin lymphoma.Blood advances · 2026Trial
- Serum TARC: a biomarker for early detection or exclusion of relapse in classic Hodgkin lymphoma.Blood advances · 2025Article
- Serum TARC dynamics during anti-PD1-based first-line Hodgkin lymphoma treatment: An analysis from the GHSG NIVAHL trial.HemaSphere · 2025Article
- Article
- ΔSUVmax adds prognostic value to early response assessment during the first-line treatment of classical hodgkin lymphoma: a retrospective cohort study.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Molecular profiling of cell-free DNA from classic Hodgkin lymphoma patients identifies potential prognostic clusters and corresponds with disease dynamics.Annals of hematology · 2025Article
- Prognostic significance of diffuse increased fluorine-18-fluorodeoxyglucose (Quantitative imaging in medicine and surgery · 2024Article
- Analysis by TeloViewCancers · 2024Article
- Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score-matched analysis.Blood advances · 2024Article
- Article
- Article
- Prognostic model using 18F-FDG PET radiomics predicts progression-free survival in relapsed/refractory Hodgkin lymphoma.Blood advances · 2023Article
- Quantitative PET-based biomarkers in lymphoma: getting ready for primetime.Nature reviews. Clinical oncology · 2023Review
- A case of complete remission of Hodgkin lymphoma confirmed histopathologically by neck dissection.Cancer reports (Hoboken, N.J.) · 2023Article
- Advances in positron emission tomography and radiomics.Hematological oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 10 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Risk-stratified treatment strategies have the potential to increase survival and lower toxicity in relapsed/refractory classical Hodgkin lymphoma (R/R cHL) patients. This study investigated the prognostic value of serum (s)TARC, vitamin D and lactate dehydrogenase (LDH), TARC immunohistochemistry and quantitative PET parameters in 65 R/R cHL patients who were treated with brentuximab vedotin (BV) and DHAP followed by autologous stem-cell transplantation (ASCT) within the Transplant BRaVE study (NCT02280993). At a median follow-up of 40 months, the 3-year progression free survival (PFS) was 77% (95% CI: 67-88%) and the overall survival was 95% (90-100%). Significant adverse prognostic markers for progression were weak/negative TARC staining of Hodgkin Reed-Sternberg cells in the baseline biopsy, and a high standard uptake value (SUV)mean or SUVpeak on the baseline PET scan. After one cycle of BV-DHAP, sTARC levels were strongly associated with the risk of progression using a cutoff of 500 pg/ml. On the pre-ASCT PET scan, SUVpeak was highly prognostic for progression post-ASCT. Vitamin D, LDH and metabolic tumor volume had low prognostic value. In conclusion, we established the prognostic impact of sTARC, TARC staining, and quantitative PET parameters for R/R cHL, allowing the use of these parameters in prospective risk-stratified clinical trials. Trial registration: NCT02280993.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.